Janssen and Theravance establish collaboration on TD-1473 for inflammatory intestinal diseases Feb. 7, 2018
Durvalumab/tremelimumab/nab-paclitaxel/gemcitabine regimen well tolerated in metastatic PDAC Feb. 7, 2018
STAT3 shown as potential therapeutic target for gastroenteropancreatic neuroendocrine tumors Feb. 7, 2018
RSS